Sandoz vs Sichuan Kelun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Sandoz Group AG (SDZ.SW)

Q3 202622 Jul – 11 Sep 2026

▲3▼1

Sandoz bets big on biosimilars as US tariff threat looms

US 100% generic tariff threat Trump threatened 100% tariffs on generic medicines, a direct risk to Sandoz's low-margin generics business. Its CEO warned tariffs would not bring production to the US and could disrupt supply of vital medicines, weighing on the shares.
A major policy threat to Sandoz's core generics business and a real counterweight to the positive news.
Strong H1 results and raised margin guidance First-half sales rose 10% to $5.76bn, with biosimilars up 25% and now a third of sales. Profit margins expanded and full-year margin guidance was raised, showing the biosimilar bet is paying off and supporting the shares.
Hard financial results that confirm the growth story and underpin the stock.
Bio100 strategy and pipeline expansion Sandoz unveiled Bio100, aiming to lead biosimilars by 2040 with over 100 products and to more than double sales in a decade. It added a Henlius partnership worth up to $322m and a $300m Slovenia plant, giving investors a long-term growth plan.
The strategy and pipeline deals set the long-term direction that drives the investment case.
New market approvals and Thailand talks Brazil approved Sandoz's semaglutide diabetes drug Owozy for launch in a $1.8bn market, and Thailand plans a cooperation deal within weeks to draw Sandoz investment. Both widen its reach, though near-term financial impact is limited.
Shows geographic expansion that adds future sales, a smaller but genuine positive driver.

August 202622 Jul – 11 Sep 2026

▲3▼1

Sandoz bets big on biosimilars as US tariff threat looms

US 100% generic tariff threat Trump threatened 100% tariffs on generic medicines, a direct risk to Sandoz's low-margin generics business. Its CEO warned tariffs would not bring production to the US and could disrupt supply of vital medicines, weighing on the shares.
A major policy threat to Sandoz's core generics business and a real counterweight to the positive news.
Strong H1 results and raised margin guidance First-half sales rose 10% to $5.76bn, with biosimilars up 25% and now a third of sales. Profit margins expanded and full-year margin guidance was raised, showing the biosimilar bet is paying off and supporting the shares.
Hard financial results that confirm the growth story and underpin the stock.
Bio100 strategy and pipeline expansion Sandoz unveiled Bio100, aiming to lead biosimilars by 2040 with over 100 products and to more than double sales in a decade. It added a Henlius partnership worth up to $322m and a $300m Slovenia plant, giving investors a long-term growth plan.
The strategy and pipeline deals set the long-term direction that drives the investment case.
New market approvals and Thailand talks Brazil approved Sandoz's semaglutide diabetes drug Owozy for launch in a $1.8bn market, and Thailand plans a cooperation deal within weeks to draw Sandoz investment. Both widen its reach, though near-term financial impact is limited.
Shows geographic expansion that adds future sales, a smaller but genuine positive driver.

Latest22 Jul – 11 Sep 2026

▲3▼1

Sandoz bets big on biosimilars as US tariff threat looms

US 100% generic tariff threat Trump threatened 100% tariffs on generic medicines, a direct risk to Sandoz's low-margin generics business. Its CEO warned tariffs would not bring production to the US and could disrupt supply of vital medicines, weighing on the shares.
A major policy threat to Sandoz's core generics business and a real counterweight to the positive news.
Strong H1 results and raised margin guidance First-half sales rose 10% to $5.76bn, with biosimilars up 25% and now a third of sales. Profit margins expanded and full-year margin guidance was raised, showing the biosimilar bet is paying off and supporting the shares.
Hard financial results that confirm the growth story and underpin the stock.
Bio100 strategy and pipeline expansion Sandoz unveiled Bio100, aiming to lead biosimilars by 2040 with over 100 products and to more than double sales in a decade. It added a Henlius partnership worth up to $322m and a $300m Slovenia plant, giving investors a long-term growth plan.
The strategy and pipeline deals set the long-term direction that drives the investment case.
New market approvals and Thailand talks Brazil approved Sandoz's semaglutide diabetes drug Owozy for launch in a $1.8bn market, and Thailand plans a cooperation deal within weeks to draw Sandoz investment. Both widen its reach, though near-term financial impact is limited.
Shows geographic expansion that adds future sales, a smaller but genuine positive driver.

Sichuan Kelun Pharmaceutical Co Ltd (002422.CS)

Q3 202627 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.

September 202627 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.

Latest27 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.